Coherence Neuro

What Coherence Neuro does

Coherence Neuro is a private neurotechnology company pioneering the field of electro-oncology — the use of implantable brain-computer interfaces to monitor and electrically modulate cancer's bioelectric signaling. Founded in 2022 in Cambridge, UK by Dr Ben Woodington (CEO) and Dr Elise Jenkins (CTO) from research conducted under Professor George Malliaras at the University of Cambridge, the company relocated its operational headquarters to San Francisco in 2025 while retaining its UK engineering base. Its flagship SOMA platform consists of three integrated components: a wireless, coin-sized MRI-transparent implant with up to 16 ultrathin biocompatible threads (SOMA-1/SOMA Implant), an over-ear wearable that wirelessly powers the implant and manages stimulation protocols, and a companion smartphone app providing real-time symptom tracking and remote clinician adjustment.

The company's core technical differentiator is bi-directional recording and stimulation: the implant continuously reads electrical activity from the tumor microenvironment and delivers targeted electrical stimulation to suppress tumor growth, driven by AI models that identify unique tumor electrical fingerprints and adapt therapy in real time. Coherence is currently investigational — not approved by the FDA or TGA — and is conducting a first-in-human trial of its CIPHER System (a thin-film cortical probe for intraoperative neurophysiological mapping) at the Royal Melbourne Hospital under neurosurgeon Dr Andrew Morokoff, with 3 patients implanted as of June 2026. The initial clinical focus is glioblastoma multiforme, where median survival is 15-18 months and five-year survival is below 10%; a second pipeline indication in pancreatic ductal adenocarcinoma was launched in 2024.

Coherence operates a clinical-trials-driven, enterprise field-sales go-to-market model targeting neurosurgeons and neuro-oncologists at leading research hospitals, with the implant placed during existing tumor resection procedures to minimize additional surgical burden. Revenue mechanics are not yet defined, as the products are investigational; the long-term business model is expected to combine implantable hardware sales with ongoing monitoring services. The company has raised approximately $12.25M across a 2023 pre-seed and a $10M November 2025 seed round led by Artesian VC.

Name

Coherence Neuro

Legal name

Coherence Neuro Global, Inc.

Website

https://coherenceneuro.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Coherence Neuro is a private neurotechnology company developing implantable brain-computer interfaces (the SOMA platform) that continuously monitor and electrically modulate tumor bioelectric activity to treat glioblastoma and other cancers, currently in first-in-human clinical trials.

Ownership category

akta.pro rank

Product category

Therapeutic Brain-Computer Interfaces

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

akta.pro secondary industry

Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)

Keywords

• Therapeutic brain-computer interfaces
• Implantable neurotechnology
• Bioelectronic cancer therapy
• Electroceutical medical devices
• Neural stimulation implants

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Implantable Medical Device Sales: Coherence Neuro generates revenue through the sale of its SOMA therapeutic BCI device — a coin-sized implant placed during brain surgery, paired with a wearable and software app. The system provides continuous tumor monitoring and electrical stimulation therapy for cancer patients, likely operating on a recurring hardware + service model typical of implantable medical devices with ongoing monitoring components.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Coherence Neuro develops and sells investigational implantable brain-computer interface systems (SOMA System and CIPHER System) that continuously monitor cancer's electrical activity and deliver targeted bioelectronic stimulation therapy. The SOMA System consists of a wireless MRI-transparent coin-sized implant, an over-ear wearable, and a smartphone app, designed to be implanted during standard brain tumor resection surgery for continuous 24/7 tumor monitoring and adaptive therapy, initially targeting glioblastoma and pancreatic cancer.

Product overview

Coherence Neuro offers a unified therapeutic neurotechnology platform centered on the SOMA system, consisting of three integrated components: the SOMA-1 implant (a wireless, MRI-transparent brain-computer interface), the SOMA wearable (an over-ear power and data management device), and the SOMA smartphone app (for real-time monitoring and clinician connectivity). The platform leverages AI and machine learning to deliver closed-loop bioelectronic therapy that continuously monitors and electrically stimulates tumor sites to prevent cancer progression. The company is also developing separate pipeline indications including pancreatic cancer and breast cancer applications.

Differentiator

Problem solved

Functional benefit

Brands

• SOMA: Therapeutic brain-computer interface device that monitors and delivers targeted electrical stimulation to treat cancer. Consists of an implantable coin-sized device, an over-ear wearable for power and data management, and a companion smartphone app.
• SOMA-1
• CIPHER System

Products and services

• SOMA System An integrated therapeutic brain-computer interface system consisting of three components: a wireless, coin-sized MRI-transparent implant with up to 16 ultrathin biocompatible threads that continuously monitors tumor electrical activity and delivers targeted electrical stimulation; an over-ear wearable device that wirelessly powers the implant and manages data and stimulation protocols with all-day battery life; and a companion smartphone app providing real-time insights, session history, and symptom tracking tools for patients and remote clinicians. Designed for cancer patients, initially targeting glioblastoma, implanted during existing tumor resection surgery.
• CIPHER System An investigational bi-directional thin-film cortical probe featuring up to 16 ultrathin biocompatible threads that record brain activity and deliver electrical stimulation with ultra-high-spatial resolution. Designed for neurophysiological mapping and stimulation during brain tumor resection surgery, evaluated in first-in-human clinical trials.

Quantifiable outcome

• Achieved first-in-human clinical trial (3 patients implanted) within 15 months of project initiation — unmatched pace in the BCI space where competitors take over 2 years for similar milestones.
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Royal Melbourne HospitalcoreStrategic or Co-development Partner · 23 June 2026Renowned neurosurgeon Dr Andrew Morokoff at the Royal Melbourne Hospital is leading Coherence Neuro's first-in-human trial of the CIPHER System, implanting the device in 3 patients during brain tumor resection surgery. Dr Morokoff is also credited as a clinical BCI pioneer and was the first to implant Synchron's vascular BCI.
• Neuralink Advisors & InvestigatorsminorStrategic or Co-development Partner · 23 June 2026Head Neurosurgeon at Neuralink, Dr Matthew MacDougal, serves as an advisor and investor in Coherence Neuro. Neuralink colleague Dr Rory Murphy is slated to be involved in US clinical trials planned over the coming years. The company leverages Neuralink-affiliated talent for clinical trial execution.
• SPARCLE ConsortiumminorStrategic or Co-development Partner · 7 July 2025An €11.5 million high-impact neurotech consortium comprising leading European neurotech companies (including ONWARD Medical and Salvia BioElectronics), research organisations (imec), and universities (University of Cambridge, Delft University of Technology). Coherence Neuro is a member focused on developing miniaturized neural implants for cancer treatment and chronic health conditions.
• University of CambridgecoreStrategic or Co-development PartnerCo-founders Dr Ben Woodington and Dr Elise Jenkins met at the University of Cambridge in 2018 conducting research in neuroengineering and neuro-oncology in Professor George Malliaras's bioelectronics lab. The company was founded from this research collaboration. Prof George Malliaras serves on the advisory team.
• Monash UniversityminorStrategic or Co-development PartnerCoherence Neuro collaborates with Monash University as part of its academic partnership network. The university logo appears alongside Cambridge, Stanford, UCSF, and Leeds as a research partner contributing to the company's electro-oncology platform development.
• Stanford UniversityminorStrategic or Co-development PartnerCoherence Neuro collaborates with Stanford University as part of its academic partnership network. Stanford's logo appears alongside Cambridge, Monash, UCSF, and Leeds as a research partner contributing to the company's neurobiology and electro-oncology research.
• UCSF (University of California, San Francisco)minorStrategic or Co-development PartnerCoherence Neuro collaborates with UCSF as part of its academic partnership network. UCSF's logo appears alongside Cambridge, Monash, Stanford, and Leeds as a research partner in the company's electro-oncology platform development.
• University of LeedsminorStrategic or Co-development PartnerDr Ryan Mathew, Professor of Neurosurgery at the University of Leeds and Principal Investigator for NIHR clinical trials, is a clinical advisor to Coherence Neuro. He is quoted supporting the company's mission: 'Treating and monitoring my patients in real time will revolutionise my practice.'

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Novocure: Novocure's Optune Gio delivers tumor treating fields (TTFields) for glioblastoma and is the established FDA-approved electrical therapy for brain cancer. Coherence is the implantable, continuous, AI-closed-loop alternative targeting the same glioblastoma population with a fundamentally different mechanism — electrical stimulation of the tumor microenvironment rather than external TTFields.
• Neuralink: Neuralink develops implantable brain-computer interfaces for cognitive and motor applications, and several of its neurosurgeons (Dr Matthew MacDougal, Dr Rory Murphy) serve as Coherence advisors and planned US investigators. While Neuralink targets motor/cognitive restoration and Coherence targets cancer therapy, both compete in the ultra-miniaturized implantable BCI hardware category and recruit from the same talent pool.
• Synchron: Synchron develops a vascular (stentrode) brain-computer interface for paralysis. Royal Melbourne Hospital's Dr Andrew Morokoff — Coherence's first-in-human trial lead — was also the first to implant Synchron's device, making the two companies share clinical infrastructure and investigator relationships in the implantable neurotechnology category.
• Blackrock Neurotech: Blackrock Neurotech builds implantable neural interfaces (Utah Array) for research and clinical applications. Like Coherence, it develops bi-directional implants that record and stimulate brain tissue, making it a relevant comparison on the implantable neural interface platform layer even though cancer is not its primary indication.
• Precision Neuroscience: Precision Neuroscience develops a thin-film cortical electrode array (Layer 7) for brain-computer interfacing. Coherence's CIPHER System uses a similar bi-directional thin-film cortical probe architecture for ultra-high-spatial resolution recording and stimulation, making Precision a directly comparable engineering peer in flexible electrode design.

Emerging players

• Motif Neurotech: Motif Neurotech develops minimally invasive brain stimulators for treatment-resistant mental health conditions, sharing with Coherence the philosophy of miniaturized, minimally invasive implantable neurotech that avoids large craniotomies. Comparable as an emerging peer in the minimally-invasive BCI category.
• ONWARD Medical: ONWARD Medical develops implantable neurostimulation systems to restore movement and function after spinal cord injury, and is a fellow SPARCLE Consortium member alongside Coherence. Both companies operate in the implantable neurostimulation category with shared EU consortium infrastructure and comparable engineering scale.
• Salvia BioElectronics: Salvia BioElectronics develops implantable neurostimulators for chronic migraine and is a SPARCLE Consortium peer of Coherence. Comparable as a European implantable neurostimulation startup of similar scale tackling a different therapeutic indication.
• Setpoint Medical: Setpoint Medical develops bioelectronic therapy devices targeting inflammatory diseases via vagus nerve stimulation, and Coherence's VP Engineering José Lepe previously brought multiple technologies to clinic at Setpoint. Comparable as a bioelectronic therapy platform peer with overlapping engineering and translational expertise.
• Galvani Bioelectronics: Galvani Bioelectronics is the Google x GlaxoSmithKline bioelectronics venture developing implantable neuromodulation therapies, and Coherence's Director of Translation Jason Miranda previously led translation at Galvani. Directly comparable on bioelectronic therapy platform ambition and translational strategy for chronic disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/coherenceneuro
• LinkedInlinkedin.com/company/coherence-neuro

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coherence Neuro